Key Highlights

Curis (NASDAQ:CRIS) (up USD 0.5964, 83.54%): Reverse Split Penny Stock Jumps as Cash Falls to USD 5.1 Million

Curis (NASDAQ:CRIS) was up 83.54%, or USD 0.5964, to USD 1.3103 in pre-market trading on November 4, 2026. No company press release, filing or clinical update dated November 2 to November 4, 2026 was identified, so the rise looks like speculative momentum.

The company's lead candidate, emavusertib, is an oral IRAK4 and FLT3 inhibitor being tested in blood cancers. Cash was USD 5.1 million at June 30, 2026, down from USD 15.0 million at March 31, 2026. A 1-for-20 reverse split took effect on July 2, 2026, and first TakeAim CLL patient data are expected in December 2026. Management said substantial additional Capital is needed, so dilution is the main risk.

MIRA Pharmaceuticals (NASDAQ:MIRA) (up USD 0.0911, 17.59%): Penny Stock Rises With No Fresh News

MIRA Pharmaceuticals (NASDAQ:MIRA) was up USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026. No company announcement dated November 2 to November 4, 2026 was identified, so momentum and speculative positioning are possibilities, not confirmed causes.

The latest items on record are pipeline updates. A press release dated October 22, 2026 reported rat study results for oral MIRA-55, and on September 17, 2026 the Ketamir-2 Phase 2a program advanced toward site initiation. Cash was USD 3,609,442 at June 30, 2026, and the 10-Q raised substantial doubt about going concern. An at-the-market agreement of up to USD 75 million could dilute holders.

Voyager Therapeutics (NASDAQ:VYGR) (up USD 0.2412, 13.19%): Penny Stock Rises Ahead of Guided Tau PET Data

Voyager Therapeutics (NASDAQ:VYGR) was up 13.19% to USD 2.07 in pre-market trading on November 4, 2026. No Voyager announcement dated November 2 to November 4, 2026 was identified. Partner Neurocrine Biosciences (NASDAQ:NBIX) reported results on November 3, but that is context, not a confirmed cause.

The company guided to tau PET data for VY7523 and first dosing of VY1706 in the fourth quarter of 2026. Cash and marketable securities were USD 148.8 million at June 30, 2026, which management said funds operations into 2028. Trial results could move shares sharply in either direction, and any Equity raise would dilute holders.

20/20 Biolabs (NASDAQ:AIDX) (up USD 0.0347, 14.77%): OneTest Webinar in Focus for a Sub-USD 1 Stock

20/20 Biolabs (NASDAQ:AIDX) was up USD 0.0347, or 14.77%, to USD 0.2696 in pre-market trading on November 4, 2026. No Earnings or financing announcement was identified, but a press release dated October 29, 2026 scheduled an investor webinar for 12:00 p.m. Eastern on November 4 covering OneTest, licensing plans and FDA strategy.

Second quarter Revenue was USD 730,571, up 36.5%, while the net loss widened to USD 1,506,343. Stockholders' equity of USD 1,620,700 sits USD 879,300 below the USD 2,500,000 Nasdaq minimum (calculated), and a bid-price deadline of January 13, 2027 applies. As a penny stock it carries Volatility and dilution risk.

Imunon (NASDAQ:IMNN) (up USD 0.0800, 8.89%): Phase 3 Ovarian Cancer Trial Keeps a Penny Stock in View

Imunon (NASDAQ:IMNN) was up USD 0.08, or 8.89%, to USD 0.98 in pre-market trading on November 4, 2026. No company release, filing or trial readout dated November 3 or November 4, 2026 was identified, so the gain appears to be trading momentum.

Its lead candidate, IMNN-001, is in the Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer. Per a June 4, 2026 release, Phase 2 median overall survival rose from 11.1 months to 14.7 months. The second quarter net loss was USD 2.8 million and cash was USD 6.9 million at June 30, 2026, against USD 7.0 million used in operations in the first half, which suggests a short horizon (calculated reading, not a company statement). A planned Stock Split has no ratio or timing, so the quoted price should be read with that in mind.

Where Things Stand

All five names are small biotech stocks and every one trades under USD 5, with three under USD 1, so the pre-market gains came with thin Liquidity and a real chance of Reversal once regular trading opens. Only AIDX has a dated event on the calendar, its webinar, while CRIS, MIRA, VYGR and IMNN had no announcement identified.

Readers should watch third quarter filings for updated cash and Going Concern language, December 2026 data from Curis, fourth quarter milestones at Voyager, and any financing or Nasdaq compliance news across the group.